Johanna Richter

Johanna Richter

Auto-generated profile, based on publicly available information

Johanna Richter

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Rheumatology
Verified
Journal Article
Closed access
IHIsabell Haase
Isabell Haase
JRJohanna Richter
Johanna Richter
MHMarie-Therese Holzer
Marie-Therese Holzer
BFBoris Fehse
Boris Fehse
NRNikolas Ruffer
Nikolas Ruffer
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger
Objectives: To explore efficacy and safety of CD19-directed Chimeric Antigen Receptor (CAR) T cell therapy in a patient with Jo1-Antisynthetase-syndrome refractory to multiple immunosuppressants, including anti-CD38 therapy, and review published cases on CAR T cell therapy in idiopathic inflammatory myopathies (IIM). Methods: Following lymphodepletion, the patient received a single infusion of autologous CD19-directed CAR T cells. Clinical, serologic, and safety outcomes were monitored over 6 months. A literature review analysed prior cases for patient characteristics, outcomes, and adverse events. Results: CAR T cell therapy was well tolerated, with only low-grade cytokine release syndrome (CRS) and no neurotoxicity. Clinical assessments demonstrated significant and rapid improvement in muscle strength, arthritis, and pulmonary function, alongside normalization of muscle enzymes and inflammatory markers. Autoantibody levels remained unchanged. Transient skin alterations resolved with low-dose glucocorticoids. CAR T cells persisted for 3 months, followed by B cell reconstitution without disease relapse. The patient remains in remission on low-dose prednisolone at 6 months. Eight previously published cases of CAR T cell therapy in IIM consistently report significant improvement, with most patients stable off immunosuppressive therapy. Hypogammaglobulinemia was frequent, but no high-grade CRS, immune-effector-cell associated neurotoxicity syndrome (ICANS) or serious infections were reported. Conclusion: CD19-directed CAR T cell therapy shows promise in refractory IIM, offering sustained clinical improvement and a favourable safety profile. The nine reported cases collectively highlight the potential of CAR T cell therapy even in patients with insufficient response to B cell/plasma-cell depleting therapies. Larger studies are needed to evaluate long-term efficacy, safety, and underlying mechanisms of CAR T cell therapy in refractory IIM.

17 November 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KRKristin Rathje
Kristin Rathje
NGNico Gagelmann
Nico Gagelmann
SHSilke Heidenreich
Silke Heidenreich
JRJohanna Richter
Johanna Richter
FMFranziska E. Marquard
Franziska E. Marquard
FAFrancis Ayuk
Francis Ayuk
Chronic graft-versus-host disease (cGvHD) is a debilitating complication following allogeneic hematopoietic stem cell transplantation, often refractory to standard therapies. Belumosudil, a selective ROCK2 inhibitor with immunomodulatory and antifibrotic properties, has emerged as a targeted treatment option, gaining FDA approval for third-line therapy in 2021. However, its clinical efficacy and safety across diverse patient populations remain incompletely characterized. We conducted a systematic review and meta-analysis of 16 studies encompassing 651 adult patients with cGvHD treated with belumosudil. Both prospective and retrospective studies reporting on overall response rate (ORR), organ-specific response, survival outcomes, and adverse events were included. Bayesian random-effects models were used to estimate pooled outcomes and assess heterogeneity. Meta-regression evaluated the impact of prior ruxolitinib exposure, disease severity, and lung involvement on treatment response. The pooled ORR was 60% (95% CI, 53-67), highest in prospective studies (73%) and lowest in retrospective multicenter cohorts (54%). Organ-specific responses were most favorable in gastrointestinal (52%) and joint/fascia (52%) involvement, but notably poor in lung cGvHD (25%). Prior ruxolitinib exposure was associated with lower ORR, while concurrent use and disease severity were not. The pooled overall survival was 87%, and failure-free survival was 57%. Adverse events were common but generally manageable; serious drug-related events occurred in ≤13% of patients, with Grade ≥3 pneumonia/lung infections in up to 17%. Belumosudil demonstrates promising efficacy and a favorable safety profile in refractory cGvHD. Our findings support further investigation in earlier treatment and disease course.

15 April 2026 in Rheumatology
Verified
Journal Article
Closed access
PKPhillip Kremer
Phillip Kremer
IHIsabell Haase
Isabell Haase
JRJohanna Richter
Johanna Richter
IKIna Kötter
Ina Kötter
DBDominic Borie
Dominic Borie
Francis Ayuketang AyukFrancis Ayuketang Ayuk
Francis Ayuketang Ayuk
Objectives: Chimeric antigen receptor (CAR)-T cell therapy recently emerged as a possible new treatment option in refractory systemic autoimmune diseases (AID). With growing evidence in B cell–mediated AID, the question arises as to its potential application in difficult to treat RA. Building on positive experience in a case of overlapping seropositive RA and SSc treated with CD19 CAR-T cells at our centre, we reviewed the available evidence on the efficacy and safety of CAR-T cell therapy in RA. Methods: The patient successfully received a single infusion of autologous CD19 CAR-T cells (KYV-101, Kyverna Therapeutics) after lymphodepletion with fludarabine and CYC. Clinical, serologic and safety outcomes were monitored over 12 months, demonstrating sustained disease remission and improvement in interstitial lung disease. Furthermore, a literature review analysed prior cases of CAR-T cell treatment in RA, focusing on patient characteristics, outcomes and adverse events. Results: Seven of eight previously published cases of CAR-T cell therapy in RA (7/8 ACPA positive) consistently reported significant improvement, with most patients remained stable off immunosuppressive therapy after a median follow-up of 9 months. High-grade cytokine release syndrome (grade 3) and immune cell–associated neurotoxicity syndrome (grade 4) was reported only in one patient. No serious infections were observed, even though transient hypogammoglobulinaemia occurred in two patients (2/8). Conclusion: The eight reported cases highlight the potential of CAR-T cell therapy, even in patients unresponsive to B cell–targeted treatments in RA. Larger and prospective studies are needed to assess its long-term efficacy and safety in the disease.

2 June 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KRKristin Rathje
Kristin Rathje
NGNico Gagelmann
Nico Gagelmann
ASArtur Schneider
Artur Schneider
JRJohanna Richter
Johanna Richter
CRChristina Rautenberg
Christina Rautenberg
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger
Splenomegaly is a hallmark feature of myelofibrosis, driven by extramedullary hematopoiesis due to progressive bone marrow fibrosis. Enlarged spleens cause significant symptoms, impair quality of life, and complicate hematopoietic stem cell transplantation (HSCT) by increasing the risk of delayed engraftment, graft failure, and relapse. While Janus kinase (JAK) inhibitors can reduce spleen size, some patients remain refractory or lose response over time. Splenic irradiation has emerged as an alternative strategy, though optimal protocols and safety profiles remain unclear. In this bicentric observational study, we evaluated the safety and efficacy of a standardized low-dose splenic irradiation protocol administered immediately prior to HSCT in patients with myelofibrosis and refractory splenomegaly. We included 11 patients with primary or secondary myelofibrosis who underwent first HSCT from 2020 to 2025. Patients received standardized low-dose splenic irradiation of 3.0 Gy fractionated into three or six daily sessions using volumetric modulated arc therapy (VMAT), administered either shortly before or partially concurrently with the conditioning regimen. We systematically monitored spleen size, hematologic parameters, molecular clearance of driver mutations, donor chimerism, and transplant-related outcomes. Median spleen size before irradiation was 25 cm, which significantly decreased to 22 cm postirradiation (median reduction: 3 cm) and further reduced to 17.7 cm by engraftment (median additional reduction: 4.3 cm). All patients achieved neutrophil engraftment within a median of 12 days and platelet engraftment was achieved by 82% within 14 days. Isolated hyperbilirubinemia occurred transiently in 82% of patients without significant clinical consequences. No occurrences of veno-occlusive disease, thrombotic microangiopathy, or hemorrhagic complications were reported. At days 30 and 100 post-transplant, full donor chimerism was achieved in 91% and 80%, with driver mutation clearance observed in 70% and 80%, respectively. With a median follow-up of 5.5 months, overall survival was 91%, with two cases of early relapse and two instances of acute graft-versus-host disease. Two patients experienced poor graft function, one requiring stem cell boost. Our study demonstrates that low-dose splenic irradiation prior to HSCT is an effective and safe adjunct treatment for managing splenomegaly in myelofibrosis patients. The standardized protocol resulted in substantial spleen size reduction, favorable engraftment kinetics, and acceptable toxicity profiles. These promising outcomes highlight splenic irradiation as a viable, less invasive alternative to splenectomy, warranting further exploration in larger prospective trials to refine protocols and confirm long-term benefits.